Literature DB >> 14529989

Comparative long-term results of surgery versus balloon valvuloplasty for pulmonary valve stenosis in infants and children.

Claire Peterson1, Johanneke J Schilthuis, Ali Dodge-Khatami, J Francois Hitchcock, Erik J Meijboom, Ger B W E Bennink.   

Abstract

BACKGROUND: We compared the long-term results of surgical valvotomy (S) versus balloon valvuloplasty (BV) for pulmonary valve stenosis in infants and children.
METHODS: Results after surgical pulmonary valvotomy (with concomitant ASD/VSD closure) (n = 62, age 2.9 +/- 3.5 years) and balloon valvuloplasty (n = 108, age 3.6 +/- 3.9 years) were analyzed. Transvalvular mean pressure gradient decrease, freedom from reintervention for restenosis, pulmonary valve insufficiency, and tricuspid valve insufficiency were considered.
RESULTS: Mean pressure gradient decreased significantly more in the surgical group (from 64.8 +/- 30.8 mm Hg to 12.8 +/- 9.8 mm Hg at a mean follow-up of 9.8 years) than after BV (decreasing from 66.2 +/- 21.4 mm Hg to 21.5 +/- 15.9 mm Hg after a mean of 5.4 years; p < 0.001). Moderate pulmonary valve insufficiency occurred in 44% after surgery, and in 11% after BV (p < 0.001). Tricuspid valve insufficiency occurred in 2% after surgery, and in 5% after BV. Restenosis occurred in 3 surgical patients (5.6%), 2 patients required reoperation, and 1 patient required a balloon valvotomy. Restenosis developed in 13 BV patients (14.1%): 6 patients were redilated and 7 patients required surgery. Surgical valvotomy led to significantly less reinterventions than balloon valvuloplasty (p < 0.04).
CONCLUSIONS: Surgical relief of pulmonary valve stenosis produces lower long-term gradients and results in longer freedom from reintervention. Balloon valvuloplasty may remain, despite these results, the preferred therapy for isolated pulmonary valve stenosis, because it is less invasive, less expensive, and requires a shorter hospital stay. Surgery should remain the exclusive form of therapy in the presence of concomitant intracardiac defects, which need to be addressed.

Entities:  

Mesh:

Year:  2003        PMID: 14529989     DOI: 10.1016/s0003-4975(03)00678-7

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Long-term pulmonary regurgitation following balloon valvuloplasty for pulmonary stenosis risk factors and relationship to exercise capacity and ventricular volume and function.

Authors:  David M Harrild; Andrew J Powell; Trang X Tran; Trang X Trang; Tal Geva; James E Lock; Jonathan Rhodes; Doff B McElhinney
Journal:  J Am Coll Cardiol       Date:  2010-03-09       Impact factor: 24.094

2.  Sympathetic overactivity in patients with pulmonary stenosis and improvement after percutaneous balloon valvuloplasty.

Authors:  Omer Alyan; Ozcan Ozdemir; Fehmi Kacmaz; Serkan Topaloglu; Cemal Ozbakir; Ayfer Gozu; Sule Korkmaz; Nizamettin Toprak
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-07       Impact factor: 1.468

3.  Pulmonary valve balloon valvuloplasty compared across three age groups of children.

Authors:  Shamsi Ghaffari; Mohammed Reza Ghaffari; Ali Reza Ghaffari; Somaie Sagafy
Journal:  Int J Gen Med       Date:  2012-05-28

4.  Restenosis after balloon valvuloplasty in a dog with pulmonary stenosis.

Authors:  Hiroshi Sunahara; Yoko Fujii; Keisuke Sugimoto; Takuma Aoki; Gou Sugahara; Kinji Shirota
Journal:  J Vet Med Sci       Date:  2014-09-23       Impact factor: 1.267

5.  Immediate Therapeutic Outcomes and Medium-term Follow-up of Percutaneous Balloon Pulmonary Valvuloplasty in Infants with Pulmonary Valve Stenosis: A Single-center Retrospective Study.

Authors:  Dian Hong; Ming-Yang Qian; Zhi-Wei Zhang; Shu-Shui Wang; Jun-Jie Li; Yi-Fan Li; Tian Liu
Journal:  Chin Med J (Engl)       Date:  2017-12-05       Impact factor: 2.628

6.  Adult congenital pulmonary valve insertion using a new bioprosthetic aortic valve: Inspiris.

Authors:  Chi Chi Do-Nguyen; Maxwell F Kilcoyne; Randy M Stevens; James Starc; Nandini Madan; Vicki Mahan; Cesar Igor Mesia; Achintya Moulick
Journal:  Clin Case Rep       Date:  2020-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.